Company Overview

The only FDA approved ophthalmic formulation of mitomycin-c. Mitosol® is a system for delivering mitomycin-c in glaucoma, surface ablation, and pterygium surgeries. Mitosol® received approval in February 2012 for glaucoma surgery and is pursuing supplemental New Drug Applications for the additional indications. Mitosol® provides a single dose of drug, formulated at the time of surgery. Closed fluid transfer assures OR personnel safety; sterile transfer is accomplished with wholly compliant sterile technique. It is stored at room temperature for up to 24 months versus the current standard of 2 weeks, if refrigerated and light shielded. Potency, formulation, and sterility are assured for every patient, yet surgical technique is unchanged. Mitosol® holds four issued patents, two pending patents, and orphan drug designation in all three indications. Mobius represents a new model in ophthalmic ventures, with capitalization that is fractional versus traditional ventures.

Mobius Therapeutics is a commercial stage venture focused on ophthalmic surgery solutions. Its first product, Mitosol®, is a system for delivering antifibrotic agents in glaucoma, refractive, and corneal surgery. Mobius is housed within the Center for Emerging Technologies in St. Louis, Missouri.

Contact

Email: ed.timm@mobiustherapeutics.com

Phone: 3146156930


Claim Content

Some information about post:

Title post: Mobius Therapeutics, LLC
ID post: 986
Post-type: companies
Author: Edward Timm

Enter your contact info to send a request to the site administrator

×